| NCT05070455 | An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIVā¢ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD) | UNKNOWN | PHASE4 | 2022-09-01 | 2023-06-30 | 2023-03-31 |
| NCT03164967 | Study to Evaluate Safety and Pharmacokinetics of BIVIGAMĀ® in Primary Immune Deficiency Subjects Aged 2 to 16 | COMPLETED | PHASE4 | 2016-12-29 | 2022-12-31 | 2022-08-30 |
| NCT01814800 | Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD) | COMPLETED | PHASE3 | 2014-02 | 2015-01 | 2014-12 |
| NCT00632463 | RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness | COMPLETED | PHASE2 | 2008-02 | 2010-05 | 2010-05 |
| NCT00538915 | Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD) | COMPLETED | PHASE3 | 2007-09 | 2009-07 | 2009-07 |
| NCT00473824 | Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation | TERMINATED | PHASE2 | 2007-05 | 2009-02 | 2009-02 |